U.S. Retinal Therapeutics Market

 


This research service provides an indepth analysis of factors affecting the growth of the U.S. retinal therapeutics market over the period 2006-2016. Included are disease and treatment overviews, product analyses, patient forecasts, product revenue forecasts, and market share analyses. In this research service, the market is segmented by retinal disease: age-related macular degeneration (AMD), diabetic retinopathy (DR)/diabetic macular edema (DME), and both branch and central retinal vein occlusion (BRVO/CRVO). Major market challenges, drivers, and restraints are identified and discussed. Additionally, a pipeline of compounds making their way through clinical trials is presented in the "Product Pipeline" section of this research service.

Regular Price: USD 4,950

Special Price USD 3,465

30% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,465

PAY BY INVOICE

Be the first to review this product

Table of Contents

U.S. Retinal Therapeutics Market, Executive SummaryU.S. Retinal Therapeutics MarketIntroductionU.S. Retinal Therapeutics Market, Market IntroductionResearch Scope and MethodologyScope and SegmentationResearch MethodologyMarket OverviewIntroductionDisease OverviewsClinical Need and Burden of DiseaseAge-related Macular DegenerationDiabetic Retinopathy and Diabetic Macular EdemaRetinal Vein OcclusionMarket TrendsMarket Engineering MeasurementsIndustry Challenges and StrategiesMarket DriversU.S. Retinal Therapeutics Market, Treatment Overview and Product PipelineTreatment OverviewAge-Related Macular DegenerationDiabetic Retinopathy and Diabetic Macular EdemaRetinal Vein OcclusionProduct PipelineAge-Related Macular DegenerationDiabetic Retinopathy and Diabetic Macular EdemaRetinal Vein OcclusionU.S. Retinal Therapeutics Market, Market AnalysisMarket Outlook and Revenue ForecastsAge-related Macular DegenerationDiabetic Retinopathy and Diabetic Macular EdemaRetinal Vein OcclusionCompetitive OverviewCompetitive StructureU.S. Retinal Therapeutics Market, AppendixDecision Support DatabasesTotal PopulationPopulation Aged 15 to 24 YearsPopulation Aged 25 to 34 YearsPopulation Aged 35 to 44 YearsPopulation Aged 45 to 54 YearsPopulation Aged 55 to 64 YearsPopulation Above 45 YearsPopulation Above 65 YearsAMD PrevalenceAMD IncidenceDiabetes PrevalenceDiabetes Incidence




Related Research

Release Date : 11-Aug-17

Region : North America

Release Date : 10-Aug-17

Region : North America

Release Date : 09-Aug-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.